FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Bus. & Prof. Code §4112 treats any out-of-state pharmacy that ships, mails or delivers prescription drugs or devices into California as a nonresident pharmacy and bars it from operating without a Board license; it must keep its home-state license, disclose owners and pharmacists, keep California records retrievable, and run a toll-free line at least 6 days and 40 hours a week. As re-enacted by AB 1503 (operative July 1, 2026), the nonresident pharmacy must designate a California-licensed pharmacist employed and working at the pharmacy as pharmacist-in-charge. The Board may inspect nonresident pharmacies at the pharmacy's cost. Under §4127.2, a nonresident pharmacy may not compound sterile drug products for shipment into California without a separate sterile compounding pharmacy license; the Board inspects before issuance and renewal (at least annually, at the pharmacy's cost) and requires adverse-effect reports within 12 hours.

The California-licensed pharmacist-in-charge requirement is new: it became operative July 1, 2026 under AB 1503 (2025). The §4112 registration requirement applies to shipments made 'pursuant to a prescription' (§4112(j)). The Board's own site (pharmacy.ca.gov) refused connections from the research environment, so Board guidance on how it is carrying out AB 1503 was not reviewed.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Bus. & Prof. Code §4052(a)(1) (amended by AB 1503, effective Jan. 1, 2026) authorizes a pharmacist to 'furnish a reasonable quantity of compounded drug product to a prescriber for office use by the prescriber.' The old rule that defined that quantity (former 16 CCR §1735.2(c): a purchase order listing the patients, delivery to and sign-off at the office, administration solely in the office) was repealed when the new nonsterile (Art. 4.5) and sterile (Art. 4.6) rules took effect Oct. 1, 2025. New 16 CCR §1735.1(a) and §1736.1(a) say compounding occurs 'pursuant to a patient specific prescription, unless otherwise specified in this article'. The only office-use provisions (§1735.1(d), §1736.1(d)) cover veterinary offices, with per-patient caps of 14 days (nonsterile), 7 days (sterile) and 28 days (ophthalmic). Limited anticipatory compounding for identified patients is allowed (§1735.1(c), §1736.1(c)). These rules apply to compounding 'by or through a licensee of the Board', which includes licensed nonresident pharmacies. The statute's office-use allowance is broader than FDA's view that 503A compounding must be patient-specific.

The Board's compounding FAQ (listed in search results as revised Jan. 7, 2026) and any policy statement on prescriber office use could not be fetched because pharmacy.ca.gov refused connections, so the Board's current reading of §4052(a)(1) under the new rules is NOT confirmed. Check with the California State Board of Pharmacy: https://www.pharmacy.ca.gov. Also new since Oct. 1, 2025: 'essentially a copy' limits (§1735.1(e), §1736.1(e)). A copy of a commercially available drug (relevant to GLP-1s) may be compounded only while it is on the ASHP/FDA shortage lists or when a documented clinically significant difference exists for an identified patient. The CCR database was current through Register 2026, No. 37 (9/11/26).

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

§4129 requires an FDA-registered outsourcing facility to be concurrently licensed by the Board as an outsourcing facility if it compounds sterile or nonsterile medication for non-patient-specific distribution within or into California. §4129.2 bars a nonresident outsourcing facility from compounding sterile or nonsterile drug products for distribution or use into California without a Board outsourcing license, renewed annually. The Board inspects before issuance and each renewal at the facility's cost and reviews its policies, prior 12-month inspection reports, and the product list reported to FDA. It requires federal cGMP compliance and reporting of discipline (10 days), recalls (24 hours), California complaints (72 hours) and adverse effects (24 hours). A Board-licensed outsourcing facility that dispenses patient-specific prescriptions does not need a separate pharmacy license but must meet pharmacy requirements.

No 2025-2026 amendment to §4129.2 was found.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; California is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Health & Safety Code Sec. 11150 limits who may issue controlled-substance prescriptions to licensed physicians and other listed licensees (NPs under B&P 2836.1, PAs under B&P 3502.1, etc.) without any state registration step. Sec. 11165.1(a)(1)(A) requires a practitioner authorized to prescribe, administer, furnish or dispense Schedule II-V controlled substances to apply for CURES access upon receipt of a federal DEA registration. CURES registration is a PDMP-access requirement, not a controlled-substance license.

Conclusion rests on the statutory scheme (authority from licensure + DEA, CURES triggered by DEA registration); no California agency page stating 'no state CSR' was opened. DEA per-location rules apply.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Health & Safety Code 11165.4 requires a practitioner who prescribes, orders, administers or furnishes controlled substances to review the patient's 12-month CURES history, no earlier than 24 hours (or the previous business day) before the first Schedule II-IV prescription, and at least once every six months thereafter if the prescription is renewed. Exemptions include drugs ordered to be administered to the patient in a clinic, outpatient setting, health facility or 'an office of a health care practitioner'; ED or procedure-related supplies of 7 days or less (nonrefillable); terminally ill patients; and system outages or timely-access problems (7-day cap). Veterinarians and pharmacists are excluded. Failure to consult results in referral to the practitioner's licensing board.

Source older than 2 years - possibly stale (last amended by Stats. 2023, Ch. 144 (AB 1731), effective 1/1/2024; text confirmed current on leginfo on 2026-09-23). Frequency: first time + at least every 6 months. Testosterone (C-III) is caught for take-home prescriptions; testosterone ordered to be administered in the practitioner's office falls within the facility/office exemption in 11165.4(c)(1)(E). Schedule V is not covered.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Bus. & Prof. Code 4170 allows a prescriber to dispense in the office only to the prescriber's own patient, for the condition being treated, without running a retail drugstore. The prescriber must meet pharmacist labeling rules (Sec. 4076), pharmacy recordkeeping and child-resistant packaging, must personally own any dispensing device, must offer a written prescription the patient may fill anywhere, and must give written disclosure of the choice to use a pharmacy. Drugs may not be furnished by a nurse or physician attendant (NPs, PAs and CNMs may hand out drugs prepackaged by a physician, manufacturer or pharmacist under protocols).

Section last amended by Stats. 2023, ch. 497 (per the code page); access date used.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Physicians treating patients in California need a California license; a narrow exception lets out-of-state physicians treat patients with immediately life-threatening conditions by telehealth (Bus. & Prof. Code 2052.5). Prescribing without an appropriate prior examination is unprofessional conduct, but that exam need not be synchronous and can be done through telehealth, including a self-screening tool or questionnaire, if the standard of care is met (Bus. & Prof. Code 2242). No California telehealth-specific controlled-substance limit was found; federal rules and California's CURES requirements still apply. IMLC: not a member.

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Medical Board of California says physicians may inject Botox or direct registered nurses or physician assistants to do so under their supervision, and that no unlicensed person, such as a medical assistant, may inject. An appropriate prior examination is required before prescriptive drugs or devices are used and may not be delegated to RNs; NPs and PAs may perform it. RNs work under standardized procedures, which let the physician be off site but immediately reachable, and the setting must be an organized health care system under physician control, not a salon or spa. The BRN also notes patients must be examined by a physician, NP or PA before treatment.

MBC FAQ and 'Bottom Line' article carry no date on the page (accessed 2026-09-23); the article describes 2006–2007 events, and the BRN sheet dates from 2013, so wording is old (possibly stale) but still posted by both boards.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Medical Board of California states that an appropriate prior examination is required whenever prescriptive drugs or devices are used and that it may not be delegated to registered nurses; after the exam the physician may delegate to an RN working under standardized procedures in an organized health care setting under physician control. Unlicensed staff may not use prescriptive drugs. California law firms advising IV clinics read this to mean each patient needs a good-faith exam by a physician, NP or PA, and that standing orders do not substitute for it. The clinic must also be physician-owned (see CPOM).

No IV-hydration-specific statement from the CA BRN was found in the BRN publications list; reports say the BRN discussed IV-hydration clinics at public meetings. The MBC principle is primary, but its application to IV hydration comes from a law-firm article (no date on page). Both accessed 2026-09-23. Admixing vitamins into IV bags outside a pharmacy may raise separate Board of Pharmacy compounding issues.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

The Medical Board of California states that a business offering medical procedures must be a physician-owned practice or a professional medical corporation with a physician majority shareholder; up to 49% may be held by other licensed professionals such as nurses or PAs, and no stock may be owned by lay persons (Corp. Code §13401.5). A physician who acts as medical director of a lay-owned business is aiding and abetting unlicensed practice (MBC Precedential Decision 2007-01-Q). B&P §2417.5 (AB 1548, 2012) makes lay-owned cosmetic businesses that employ physicians liable for insurance-fraud penalties. MSO structures are commonly used.

MBC pages have no date (accessed 2026-09-23). A 2025–2026 compilation reports new California laws SB 351 and AB 1415 (effective 2026-01-01) tightening private-equity/MSO control over physician practices.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

The Medical Board says PAs and RNs (not LVNs) may use lasers or IPL under a physician's supervision, and that unlicensed medical assistants, LVNs, cosmetologists, electrologists and estheticians may not perform these treatments under any circumstances. A prior examination by a physician (or NP/PA) is required before the device is used. Board regulation 16 CCR §1364.50 requires a physician with relevant training to be "immediately available" (contactable without delay) whenever a licensed provider performs an elective cosmetic laser or IPL procedure, with provisions written into standardized procedures. There is no separate laser-technician licence.

The BRN sheet (2013) reproduces the proposed §1364.50 text then pending at OAL; the adopted text was not separately fetched. The MBC FAQ has no date (accessed 2026-09-23).

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

California's clinical laboratory law applies 'to all clinical laboratories in California or receiving biological specimens originating in California' for testing (Bus. & Prof. Code §1241(a)), so an out-of-state lab needs a California license from CDPH Laboratory Field Services in addition to CLIA. A 2021 law-firm review notes that out-of-state labs taking California specimens for moderate- or high-complexity testing must hold an out-of-state license. Exemptions include federal and public health labs, forensic-only and research labs that do not report patient results, and OTC self-testing. California also licenses laboratory personnel.

Out-of-state labs: yes. Regulator: CDPH Laboratory Field Services (LFSCLIA@cdph.ca.gov). Fox Rothschild review is from 2021 (older than 2 years) but is consistent with the current statute.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

Bus. & Prof. Code §1246.5 says 'any person may request, and any licensed clinical laboratory or public health laboratory may perform' the listed tests: pregnancy, glucose, cholesterol, occult blood, and tests for which an FDA-approved over-the-counter test kit exists. A test approved only as an OTC collection device does not qualify. Otherwise, §1288 limits labs to accepting test assignments from persons licensed in the healing arts. The lab must hold a California license, which also applies to out-of-state labs (see lab licensing).

Take-home consumer kits for California residents qualify only if the test is on the §1246.5 list or has an FDA-approved OTC equivalent.

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Bus. & Prof. Code §684 (added by SB 512 in 2017, amended 2018) applies to licensed health care practitioners performing stem cell therapy (therapy using HCT/Ps, with listed exclusions) that is FDA-regulated but not FDA-approved. The practitioner must post a notice ('THIS NOTICE MUST BE PROVIDED TO YOU UNDER CALIFORNIA LAW...') at the office entrance and give it to the patient before the first treatment, on paper at least 8.5 x 11 inches in 40-point type. Practitioners working under an FDA IND or IDE are exempt. There is no fine for a first violation; later violations can bring fines of up to $1,000 each. The law requires disclosure only and does not authorize any therapy. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

As reviewed, §684 contains no signed-consent or advertising-notice requirement, unlike the Washington, Utah, Florida and Georgia laws. The RAPS article is from 2017 (older than 2 years), but the statute is current.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Toxic-Free Cosmetics Act (H&S §108980; AB 2762 and later amendments, including AB 60 of 2025): since Jan 1, 2025, cosmetics may not contain intentionally added dibutyl or diethylhexyl phthalate, formaldehyde, paraformaldehyde, methylene glycol, quaternium-15, mercury, isobutyl- or isopropylparaben, m- or o-phenylenediamine, or listed PFAS. More substances are banned from Jan 1, 2027, including lily aldehyde, styrene, cyclotetrasiloxane, certain dyes and musks, and boron compounds such as boric acid and borates. Technically unavoidable trace amounts are excepted. H&S §108981.5 (AB 2771) bans cosmetics with any intentionally added PFAS from Jan 1, 2025. Under the Safe Cosmetics Act (H&S §111792), manufacturers with at least $1 million in annual cosmetic sales must report products containing chemicals known to cause cancer or reproductive toxicity to CDPH. The Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H&S §111792.6) requires reporting of fragrance and flavor ingredients on designated hazard lists and of listed fragrance allergens, starting Jan 1, 2022. Civil Code §1834.9.5 (operative Jan 1, 2020) bars selling cosmetics developed or manufactured using animal tests conducted after that date, with exceptions; penalties are $5,000 plus $1,000 per day.

AB 60 (Stats. 2025, ch. 432, effective Jan 1, 2026) amended §108980, adding a warning label for boric-acid vaginal suppositories from Jan 1, 2027 and a ban from Jan 1, 2035 unless FDA-regulated as a drug. Proposition 65 warning rules apply to consumer products generally and were not reviewed here. Federal MoCRA and FDA cosmetic and OTC sunscreen rules apply in every state.